Pharmaxis Ltd (PMXSF) Research

Pharmaxis Ltd, an Australian biopharmaceutical company established in 1998 and headquartered in Frenchs Forest, specializes in the global research, development, and commercialization of therapeutic products for fibrotic and inflammatory diseases. Its business is organized into two main divisions: the Mannitol Respiratory Business and New Drug Development. The company currently markets Bronchitol, an inhaled dry powder medication for the treatment of cystic fibrosis, and Aridol, a diagnostic tool used to detect hyper-responsive airways and assist in the diagnosis and management of asthma. Pharmaxis also has a robust development pipeline featuring several investigational therapies. These include oral pan-lysyl oxidase (LOX) inhibitors aimed at myelofibrosis and various cancers; topical pan-LOX inhibitors designed to minimize skin scarring after events such as accidents, surgery, or burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic conditions like kidney, pulmonary, liver, and cardiac fibrosis; and compounds focused on neuroinflammatory diseases via semicarbazide-sensitive amine oxidase. Furthermore, the company is developing Orbital, a dry powder inhaler intended for the efficient delivery of high drug doses to the lungs.

Open Pharmaxis Ltd (PMXSF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.